RISK

Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services

Retrieved on: 
Thursday, December 23, 2021
Oncology, Health, Technology, Other Technology, Research, Science, Pharmaceutical, Precision medicine, Genetic testing, Failure, Drug development, Cooley LLP, Annual report, Genome, Technology, Johns Hopkins University, NYSE, Risk, Patient, LinkedIn, Hart–Scott–Rodino Antitrust Improvements Act, NGS, CEO, Regulation of tobacco by the U.S. Food and Drug Administration, Science, Growth, Review, Liquid biopsy, Acquisition, SEC, Health, COVID-19, Solution, LLP, Large-cell lung carcinoma, Hospital, Information technology, Public opinion, Genomics, Cancer, Laboratory, Resolution, Research, Multimedia, Food, Clinical trial, Lead, LH, RISK, Biomarker, FDA, Local government, Medical imaging, Fine chemical, Pharmaceutical industry, LabCorp, Labcorp, PGDx, LABCORP, PGDX

PGDxs comprehensive portfolio of next-generation sequencing products will meaningfully add to our breadth of capabilities, in line with our strategic priority to lead in oncology.

Key Points: 
  • PGDxs comprehensive portfolio of next-generation sequencing products will meaningfully add to our breadth of capabilities, in line with our strategic priority to lead in oncology.
  • Next-generation sequencing, including liquid biopsy, represents the future of treatment and response monitoring in people with cancer.
  • Liquid biopsy testing can also eliminate the need for an invasive biopsy procedure, reducing costs and improving patient outcomes.
  • PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.

CIRCOR Announces CFO Transition

Retrieved on: 
Wednesday, December 15, 2021
Aerospace, Other Manufacturing, Manufacturing, Aerospace, Defense, AND, Solution, Director, Company, Board, Control, NYSE, RISK, Fluid, Business development, Act, CIR, COVID-19, WE, Acquisition, Industrial, Knowledge, CFO, Leadership, EPS, Reliance, GAAP, Senior, Â, Management, Risk management

AJ Sharma, currently CIRCORs Senior Vice President, Business Development, will serve as the interim CFO.

Key Points: 
  • AJ Sharma, currently CIRCORs Senior Vice President, Business Development, will serve as the interim CFO.
  • On behalf of the Board of Directors and everyone at CIRCOR, I want to thank Abhi for his financial leadership and contributions to CIRCOR, and we wish him the best in his future endeavors, said Scott Buckhout, President & Chief Executive Officer of CIRCOR.
  • With AJs long tenure at CIRCOR, his extensive knowledge of our businesses, financial acumen and strong leadership, I have complete confidence he will successfully lead the team through this transition.
  • CIRCOR markets its solutions directly and through various sales partners to more than 14,000 customers in approximately 100 countries.

Labcorp Announces Initiatives to Enhance Shareholder Value

Retrieved on: 
Thursday, December 9, 2021
Cardiology, Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Hospitals, Genetics, Science, Public opinion, NYSE, Information technology, Company, Review, SEC, Health, RISK, Growth, Form 10-Q, Local government, Failure, Board of directors, Drug development, LH, Patient, CEO, Board, Science, Autoimmunity, Policy, Barclays, Sustainability Accounting Standards Board, Time, COVID-19, Program, Share repurchase, LinkedIn, Hospital, Annual report, Goldman Sachs, Launch pad, Investment, Management, Car rental, Financial adviser, Renewable energy, Risk management

Labcorp (NYSE: LH) (the Company), a leading global life sciences company, today announced actions that its Board of Directors (the Board) and management team have taken to enhance shareholder returns.

Key Points: 
  • Labcorp (NYSE: LH) (the Company), a leading global life sciences company, today announced actions that its Board of Directors (the Board) and management team have taken to enhance shareholder returns.
  • The Board unanimously concluded that the Companys existing structure is in the best interest of all stakeholders at this time and represents compelling opportunities to grow and create significant shareholder value.
  • Management and the Board are committed to continuing to evaluate all avenues for enhancing shareholder value.
  • Learn more about Labcorp at www.Labcorp.com , or follow us on LinkedIn and Twitter @Labcorp .

Streamline USA, Inc. Achieves Reg. A+ - TIER 2

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Company, EDGAR, RISK, OTC, Orientation, EST, Tier 2, CPA, LLC, Acquisition, Language, Wall Street, Security (finance)

HOLLYWOOD, Calif., Dec. 8, 2021 /PRNewswire/ -- The United States Securities and Exchange Commission has qualified the Reg. A+ - Tier 2 offering of Streamline USA, Inc., on November 29, 2021, at 9 a.m.

Key Points: 
  • A+ - Tier 2 offering of Streamline USA, Inc., on November 29, 2021, at 9 a.m.
    Company Co-Founder, Ruben Igielko-Herrlich, stated: "We are thrilled that the S.E.C.
  • for greater specificity, we were able to greatly improve our explanation to investors, as far as the various components of our business."
  • Company Co-Founder, James Ma, said: "We were able to explain better, and in a clear and concise manner, consistent with the S.E.C.
  • FORWARD LOOKING STATEMENT- Hollywood, California - Streamline USA, Inc. is registered with the United States Securities and Exchange Commission.

Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs

Retrieved on: 
Monday, November 29, 2021
GMP, Patient, Government, Security (finance), Coronavirus, CEO, Energy Independence and Security Act of 2007, Technology, Time, Annual report, Diabetes, Company, Hospital, Partnership, Tissue engineering, JV, Entrepreneurship, U.S. Securities and Exchange Commission, Laboratory, Program, An Act to exempt a particular class of securities from the Securities and Exchange Act, Research, GLOBE, RISK, B cell, Hematology, Â, Regenerative medicine, CGT, Intention, Therapy, Protest and strikes of the CGT union 2021, NASDAQ, Securities Act of 1933, Pharmaceutical industry

GERMANTOWN, Md., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announces that its joint venture (JV) with Theracell Advanced Biotechnology S.A. (Theracell) in Greece has been designated a “Priority Investment of Strategic National Importance.” The designation was awarded by Enterprise Greece, the official Greek national investment and trade promotion agency, which is responsible for the allocation of the government funds.

Key Points: 
  • The designation was awarded by Enterprise Greece, the official Greek national investment and trade promotion agency, which is responsible for the allocation of the government funds.
  • In addition, the JV has been approved to receive a grant of up to 32 million from the Greek government upon its request depending on the JVs requirements.
  • The funds are also intended to support the process development and manufacturing of the therapies at the clinical sites, utilizing Orgenesis Mobile Processing Units and Labs (OMPULs).
  • OMPULs are multi-purpose mobile autonomous good manufacturing practice (GMP) facilities intended to develop, optimize and manufacture cell and gene therapies at the point of care.

Labcorp to Acquire Toxikon, Expanding Nonclinical Development Testing Capabilities for Pharmaceutical, Biotech and Medical Device Clients

Retrieved on: 
Thursday, November 18, 2021
Health, Medical Devices, Other Health, Research, Science, Pharmaceutical, Biotechnology, Patient, IDE, Information technology, CEO, Review, Annual report, Local government, Acquisition, Hospital, NYSE, Hart–Scott–Rodino Antitrust Improvements Act, Health, SEC, Solution, Health care reform, COVID-19, CRO, Biotechnology, RISK, LH, Knowledge, Public opinion, LinkedIn, Multimedia, Drug development, Toxicology, Failure, Growth, Fine chemical, Pharmaceutical industry, Toxikon, Labcorp, TOXIKON, LABCORP

View the full release here: https://www.businesswire.com/news/home/20211118005744/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211118005744/en/
    Adding Toxikon underscores our commitment to nonclinical development and advances our capabilities for both drug development and medical device testing, said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development.
  • This acquisition extends Labcorps portfolio of full-service drug development and medical device solutions from discovery to market approval.
  • Toxikons strategic location allows Labcorp to further engage with large pharmaceutical companies and biotech firms in the region on nonclinical work, as well as facilitating entry into medical device investigational device exemption (IDE) submissions.
  • As such, Toxikon will also complement Labcorps existing nonclinical medical device efficacy and safety testing and the associated clinical work performed by Labcorps medical device and diagnostics unit.

Dell Technologies Used Palisade’s Predictive Analytics Tools to Optimize Global Supply Chain

Retrieved on: 
Wednesday, November 17, 2021
Hardware, Logistics, Supply Chain Management, Transport, Technology, Software, Dell Technologies, Technology, Decision-making, Solution, Global, Policy, Monte Carlo, Research, Risk, Eriz, Atmosphere, Dell, RISK, Â, Warehouse, Retail, Risk management, Online shopping

Dell Technologies adopted a hybrid replenishment strategy using both ocean and air shipping to ensure inventory and service levels while reducing logistics costs.

Key Points: 
  • Dell Technologies adopted a hybrid replenishment strategy using both ocean and air shipping to ensure inventory and service levels while reducing logistics costs.
  • The supply chain strategy team evaluated the static initial inventory policy to identify an optimal solution that would minimize total fulfillment cost.
  • Francisco Erize, a supply chain digital automation product owner at Dell Technologies, has more than 15 years of experience at Dell in operations research and business improvement.
  • Erize is focused on supply chain technical solutions to improve demand forecasting and strategic supply planning.

Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies

Retrieved on: 
Monday, November 15, 2021
Population, GMP, Â, Therapy, Tel Aviv Sourasky Medical Center, Security (finance), NASDAQ, CEO, Technology, Protest and strikes of the CGT union 2021, Coronavirus, Fausto Pocar, An Act to exempt a particular class of securities from the Securities and Exchange Act, Research, CGT, Securities Act of 1933, Annual report, Hospital, U.S. Securities and Exchange Commission, GLOBE, Development, Innovation, Drug Quality and Security Act, Diabetes, RISK, Patient, JV, Pharmaceutical industry

(NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, has entered into a collaboration agreement (Agreement) with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.

Key Points: 
  • (NASDAQ: ORGS) (Orgenesis or the Company), a global biotech company working to unlock the full potential of cell and gene therapies, has entered into a collaboration agreement (Agreement) with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.
  • The parties also plan to deploy Orgenesis Mobile Processing Units and Labs (OMPULs) onsite to support joint research and validation activities for advanced cell and gene therapies developed by both Orgenesis and the Tel Aviv Sourasky Medical Center.
  • Vered Caplan, CEO of Orgenesis, stated, It is an honor to collaborate with the Tel Aviv Sourasky Medical Center and Professor Irit Avivi, Director of Hematology, to advance the clinical development of potentially breakthrough cell and gene therapies.
  • A 1500-bed world-class governmental academic medical center, Tel Aviv Sourasky Medical Center serves a population of one million people, including residents from the greater Tel Aviv area and visitors to the metropolis.

Abercrombie & Fitch Co. to Report Third Quarter 2021 Results on November 23, 2021

Retrieved on: 
Friday, October 29, 2021
Private Securities Litigation Reform Act, Company, Abercrombie & Fitch Co. v. Hunting World, Inc., RISK, COVID-19, Individual, Online shopping

Words such as estimate, project, plan, believe, expect, anticipate, intend, should, are confident, and similar expressions may identify forward-looking statements.

Key Points: 
  • Words such as estimate, project, plan, believe, expect, anticipate, intend, should, are confident, and similar expressions may identify forward-looking statements.
  • Except as may be required by applicable law, we assume no obligation to publicly update or revise our forward-looking statements.
  • Risks and uncertainties related to the duration and impact of the COVID-19 pandemic on the Company and the factors disclosed in ITEM 1A.
  • Abercrombie & Fitch Co. operates over 730 stores under these brands across North America, Europe, Asia and the Middle East, as well as the e-commerce sites www.abercrombie.com , abercrombiekids.com , www.hollisterco.com , www.gillyhicks.com , and www.socialtourist.com .

Jennifer Esposito Makes Directorial Debut With Independent Feature Film Fresh Kills

Retrieved on: 
Wednesday, October 27, 2021
Entertainment, Professional Services, Film & Motion Pictures, Finance, ACT, Woman, Good Time, SELL, AS, ISIN, THE, TIME, Regulation D, Athlete, Summer, Roman Catholic Diocese of La Crosse, Securities Act of 1933, FDIC, Lifting, ABLE, BUY, NOT, DATE, INCLUDE, Horizon, Company, OTC Markets Group, YOU, Man, Fresh Kills, Male, FRESH, NATURAL, Fear, Solution, World Federation of Exchanges, Violence, Initial public offering, OF, Industry, III, PayPal, OR, BUT, AND, FUTURE, Silicon, Movement, WHO, EQUITY, Sale, TO, SALES, Technology, IPO, Wall Street, USDC, ANY, ARE, World government, Software, RISK, RISKS, Fresh, Reg, Film, Sex industry, Security (finance), Cryptocurrency, Fresh Kills, Horizon, Upstream, MERJ, FRESH KILLS, HORIZON, UPSTREAM, MERJ

Actress Jennifer Esposito will make her directorial debut with the independent feature film Fresh Kills, a gripping drama that tells the story of the loyal women of an organized crime family that dominated some of the boroughs of New York City in the late 20th century.

Key Points: 
  • Actress Jennifer Esposito will make her directorial debut with the independent feature film Fresh Kills, a gripping drama that tells the story of the loyal women of an organized crime family that dominated some of the boroughs of New York City in the late 20th century.
  • In a groundbreaking departure from traditional film financing, the Fresh Kills production will be financed by an offering on the Upstream Exchange, which today announced a $3.5 million Initial Public Offering IPO of securities1 by Fresh Kills, Inc. ("Fresh Kills).
  • Fresh Kills is the work of actress-turned-filmmaker Jennifer Esposito (Summer of Sam, Crash), a Hollywood veteran and advocate for advancing equality in the film industry.
  • Apart from purchasing Fresh Kills securities, fans in the United States and worldwide can support the Fresh Kills film and movement by purchasing FRESH NFTs (nonfungible tokens) which feature exciting opportunities related to the film, as well as images, videos, or content from the film, cast and crew.